Are Outcomes-Based Managed Entry Agreements Dead In Europe?
Executive Summary
Outcomes-based managed entry agreements designed to help ensure access to expensive new medicines are not sustainable and have so far failed to provide a solution to the problem of funding costly innovative drugs, according to Ad Schuurman from ZIN, the Dutch National Healthcare Institute.
You may also be interested in...
Budget Pact, Not Compulsory Licensing Is Solution To Pricing Woes, Says Dutch Pharma
The Dutch Pharmaceutical industry association is calling for an agreement with the government to control the medicines budget and wants to start a new conversation about drug pricing.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.